EMBARK Data Support Delandistrogene Moxeparvovec for DMD Across All Study End Points
Over a 52-week treatment period, the gene therapy demonstrated robust evidence for a clinically meaningful benefit, including across several prespecified functional secondary end points vs placebo.
Doug Ingram Douglass Ingram Craig Mcdonald Uc Davis Health Craig Mcdonald Uc Davis Health Department Of Physical Medicine Sarepta Therapeutics
Source: ajmc.com